ReviR Therapeutics develops small-molecule RNA-targeting therapies using an AI-driven discovery approach. The company leverages its VoyageR platform to discover and optimize chemical matter against RNA targets, including splice modulation technologies. Its initial therapeutic focus includes Huntington’s disease, Charcot‑Marie‑Tooth disease, amyotrophic lateral sclerosis, and other neurological and rare genetic disorders with limited treatment options. ReviR plans to further augment the VoyageR platform and advance proprietary programs toward clinical development. The company is led by CEO Dr. Peng Yue and was founded in 2021 in Brisbane, CA. Financially, ReviR closed a $30M Series A in the reported round, bringing total capital raised to $54M.

Total raised

$30M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2024